- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
BTI sells MSI system to German hospital
Magnetic source imaging developer Biomagnetic Technologies ofSan Diego last month announced the sale of a Magnes 2500 WH systemto the University of Konstanz in Germany. The university willuse the scanner to conduct psychiatric research.The order is the
Magnetic source imaging developer Biomagnetic Technologies ofSan Diego last month announced the sale of a Magnes 2500 WH systemto the University of Konstanz in Germany. The university willuse the scanner to conduct psychiatric research.
The order is the eighth for BTI's new Whole Head scanner, whichsells for between $1.5 million and $2.5 million (SCAN 3/15/95).BTI began shipping Magnes 2500 WH systems to international customersin July.
BTI cited the delay in Magnes 2500 WH shipments as the reasonfor a sharp drop in revenue for its first nine months (end-June).BTI posted revenues of $865,000 and a net loss of $9.2 million,compared with revenues of $6.1 million and a net loss of $5.7million in the same period a year ago.
In other news, BTI received 510(k) clearance for its Magnes IIMSI device. BTI hopes that the agency's familiarity with MagnesII will pay off in its review of Magnes Whole Head, a more sophisticatedMSI scanner that entered the 510(k) process in July. The WholeHead scanner employs 148 channels, twice as many as Magnes II,and BTI plans to emphasize Whole Head sales when that productis cleared.
Can Generative AI Facilitate Simulated Contrast Enhancement for Prostate MRI?
January 14th 2025Deep learning synthesis of contrast-enhanced MRI from non-contrast prostate MRI sequences provided an average multiscale structural similarity index of 70 percent with actual contrast-enhanced prostate MRI in external validation testing from newly published research.
Can MRI Have an Impact with Fertility-Sparing Treatments for Endometrial and Cervical Cancers?
January 9th 2025In a literature review that includes insights from recently issued guidelines from multiple European medical societies, researchers discuss the role of magnetic resonance imaging (MRI) in facilitating appropriate patient selection for fertility-sparing treatments to address early-stage endometrial and cervical cancer.
